Abstract
An α-MSH peptide analogue, named MTII (Ac-Nle-c[Asp-His-D-Phe-Arg-Trp-Lys]- NH2), is one of the most important ligands of melanotropic receptors but are relatively nonselective. In order to improve the melanotropic activities of the well-characterized MTII analogues, we report here a new analogue by modifying the core structure as well as the size of the cyclic region of MTII peptide. The analogue peptide, Ac-Nle-c[Asp-His-D-Phe-Lys-Trp-Gly-Lys]-OH (F Peptide), in which we replaced Arg at position 8 with Lys and added a Gly to position 10 of the MTII peptide sequence, was synthesized and used as a new melanotropic hormone in controlling rapid color changes in frogs by its actions on mobilizing pigment granule movements within chromatophores. The in vivo responses of chromatophores to MTII and the related analogue F Peptide were studied in frogs. The results show that the F Peptide was a superpotent agonist with similar melanotropic activity to the MTII peptide according to MTII peptide by in vivo studies. The analogue also exhibited ultraprolonged melanotropic activity. The F peptide can be useful in the study of numerous physiological processes, particularly when superpotent and prolonged melanotropic activity is desired.
Keywords: Antagonist, F peptide, frog skin, Melanophore Index, melanotropic activity, MTII peptide.
Graphical Abstract
Protein & Peptide Letters
Title:Analogue of Melanotan II (MTII): A Novel Melanotropin with Superpotent Action on Frog Skin
Volume: 22 Issue: 8
Author(s): Liqian Gao, Zhiqiang Yu, Dan Meng, Fang Zheng, Yong S. Ong, Peng Miao, Su S. Lee and Longping Wen
Affiliation:
Keywords: Antagonist, F peptide, frog skin, Melanophore Index, melanotropic activity, MTII peptide.
Abstract: An α-MSH peptide analogue, named MTII (Ac-Nle-c[Asp-His-D-Phe-Arg-Trp-Lys]- NH2), is one of the most important ligands of melanotropic receptors but are relatively nonselective. In order to improve the melanotropic activities of the well-characterized MTII analogues, we report here a new analogue by modifying the core structure as well as the size of the cyclic region of MTII peptide. The analogue peptide, Ac-Nle-c[Asp-His-D-Phe-Lys-Trp-Gly-Lys]-OH (F Peptide), in which we replaced Arg at position 8 with Lys and added a Gly to position 10 of the MTII peptide sequence, was synthesized and used as a new melanotropic hormone in controlling rapid color changes in frogs by its actions on mobilizing pigment granule movements within chromatophores. The in vivo responses of chromatophores to MTII and the related analogue F Peptide were studied in frogs. The results show that the F Peptide was a superpotent agonist with similar melanotropic activity to the MTII peptide according to MTII peptide by in vivo studies. The analogue also exhibited ultraprolonged melanotropic activity. The F peptide can be useful in the study of numerous physiological processes, particularly when superpotent and prolonged melanotropic activity is desired.
Export Options
About this article
Cite this article as:
Gao Liqian, Yu Zhiqiang, Meng Dan, Zheng Fang, Ong S. Yong, Miao Peng, Lee S. Su and Wen Longping, Analogue of Melanotan II (MTII): A Novel Melanotropin with Superpotent Action on Frog Skin, Protein & Peptide Letters 2015; 22 (8) . https://dx.doi.org/10.2174/0929866522666150622101944
DOI https://dx.doi.org/10.2174/0929866522666150622101944 |
Print ISSN 0929-8665 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5305 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Clinical Update: Treatment of Glioblastoma Multiforme with Radiolabeled Antibodies that Target Tumor Necrosis
Current Cancer Therapy Reviews OPLS-DA as a Suitable Method for Selecting a Set of Gene Transcripts Discriminating RAS- and PTPN11-Mutated Cells in Acute Lymphoblastic Leukaemia
Combinatorial Chemistry & High Throughput Screening Synthesis, Characterization by Means of IR, 1H, 13C - NMR and Biological Investigations on New Diorganotin Carboxylic Acid Derivatives
Letters in Drug Design & Discovery Epigallocatechin-3-gallate(EGCG): Mechanisms and the Combined Applications
Combinatorial Chemistry & High Throughput Screening Iron Chelators in Medicinal Applications - Chemical Equilibrium Considerations in Pharmaceutical Activity
Current Medicinal Chemistry Biomarkers in Silent Traumatic Brain Injury
Current Pharmaceutical Design Role of Inflammatory Mediators in Angiogenesis
Current Drug Targets - Inflammation & Allergy Procyanidins and Their Healthy Protective Effects Against Type 2 Diabetes
Current Medicinal Chemistry 19F: A Versatile Reporter for Non-Invasive Physiology and Pharmacology Using Magnetic Resonance
Current Medicinal Chemistry Emerging Insights in the Role of Tissue Factor in Cancer
Current Genomics Nanocarriers Conjugated with Cell Penetrating Peptides: New Trojan Horses by Modern Ulysses
Current Pharmaceutical Biotechnology Single Autosomal Trisomy in Acute Myeloid Leukemia and Myelodysplastic Syndrome
Current Genomics Androgen Receptor in Human Health: A Potential Therapeutic Target
Current Drug Targets Biochemical Strategies to Anticoagulation: A Comparative Overview
Current Vascular Pharmacology Targeted Therapy Options for Treatment of Bone Metastases; Beyond Bisphosphonates
Current Pharmaceutical Design Recent Advances in Liver X Receptor Biology and Chemistry
Current Topics in Medicinal Chemistry Phytoestrogens and Mitochondrial Biogenesis in Breast Cancer. Influence of Estrogen Receptors Ratio
Current Pharmaceutical Design Blood Coagulation and the Risk of Atherothrombosis
Current Genomics Novel Methods for the Non-Invasive Administration of DNA Therapeutics and Vaccines
Current Drug Delivery Biological Potential of Halfsandwich Ruthenium(II) and Iridium (III) Complexes
Anti-Cancer Agents in Medicinal Chemistry